Guggenheim on Celldex Therapeutics (CLDX): 'CLDX Remains Leader In The Mast Cell Space'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $90.00 price target on Celldex Therapeutics (NASDAQ: CLDX)The analyst comments "Key ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
